Zacks
GILD Exercises Option to License Assembly Bio's Herpes Programs
📈
AI Sentiment
Highly Positive
8/10
- Home
- CRMD
CRMD
CorMedix Inc.
as of 12-24-2025 12:45pm EST
$12.05
+$0.07
+0.58%
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 943.9M | IPO Year: | 2010 |
| Target Price: | $17.43 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $17.43 | Next Earning Date: | 11-12-2025 |
| Revenue: | $214,303,672 | Revenue Growth: | 1647.67% |
| Revenue Growth (this year): | 627.89% | Revenue Growth (next year): | 40.95% |
AI-Powered CRMD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 81.33%
81.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of CorMedix Inc. (CRMD)
Lefkowitz Steven W
Sell
Director
CRMD Dec 9, 2025
Avg Cost/Share
$11.88
Shares
40,000
Total Value
$475,200.00
Owned After
80,498
SEC Form 4
Dillione Janet
Sell
Director
CRMD Dec 9, 2025
Avg Cost/Share
$12.00
Shares
34,000
Total Value
$408,000.00
Owned After
48,473
SEC Form 4
Dillione Janet
Sell
Director
CRMD Dec 2, 2025
Avg Cost/Share
$10.00
Shares
46,657
Total Value
$466,570.00
Owned After
48,473
SEC Form 4
Dillione Janet
Sell
Director
CRMD Nov 14, 2025
Avg Cost/Share
$11.42
Shares
30,000
Total Value
$342,600.00
Owned After
48,473
SEC Form 4
Kaplan Myron
Buy
Director
CRMD Oct 23, 2025
Avg Cost/Share
$11.02
Shares
25,000
Total Value
$275,500.00
Owned After
201,034
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lefkowitz Steven W | CRMD | Director | Dec 9, 2025 | Sell | $11.88 | 40,000 | $475,200.00 | 80,498 | |
| Dillione Janet | CRMD | Director | Dec 9, 2025 | Sell | $12.00 | 34,000 | $408,000.00 | 48,473 | |
| Dillione Janet | CRMD | Director | Dec 2, 2025 | Sell | $10.00 | 46,657 | $466,570.00 | 48,473 | |
| Dillione Janet | CRMD | Director | Nov 14, 2025 | Sell | $11.42 | 30,000 | $342,600.00 | 48,473 | |
| Kaplan Myron | CRMD | Director | Oct 23, 2025 | Buy | $11.02 | 25,000 | $275,500.00 | 201,034 |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Zacks
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
📈
AI Sentiment
Highly Positive
9/10
Zacks
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
📈
AI Sentiment
Highly Positive
9/10
Zacks
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains?
📈
AI Sentiment
Highly Positive
9/10
Zacks
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
📈
AI Sentiment
Highly Positive
8/10
Zacks
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
📈
AI Sentiment
Highly Positive
8/10
Compare CRMD vs Leading Stocks
See how CRMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.